Ranjeet Ajmani To Speak at WHIF25
Ranjeet Ajmani, Chief Executive Officer- Asia at Aegros, reposted from World Health Innovation Forum on LinkedIn:
”Self-Reliance in Plasma Products: A Global Imperative
It is both an honor and a privilege to share my thoughts on how India can become self-reliant in the production of plasma-derived medicines (PDMPs), and how this can help many other developing countries improve their plasma collection, regulatory frameworks, and public health policies.
By collaborating on these areas, we can enable countries to either pursue contract fractionation or even set up their own fractionation plants, ensuring they meet the urgent healthcare needs of their populations.
Considering the current geopolitical landscape, this initiative is more critical than ever.
Self-sufficiency in plasma products not only strengthens national healthcare systems but also reduces dependence on international suppliers, mitigating risks tied to global supply chain disruptions.
Now is the time for sharing knowledge, expertise, and learning for the greater good.
After all, patients are patients, and their right to safe, accessible PDMPs should never be questioned.
Together, we can build a future where no one is left behind in the pursuit of better healthcare.”
Quoting World Health Innovation Forum‘s post:
”The visionary shaping Asia’s plasma biopharma landscape!
We are honoured to welcome Dr. Ranjeet Ajmani, Chief Executive Officer – Asia at Aegros, as a speaker at the World Health Innovation Forum (WHIF) 2025.
A pioneer in plasma-derived biopharmaceuticals, Dr. Ajmani has redefined India’s plasma industry, from conceptualizing and executing India’s first contract plasma fractionation model to successfully converting over 100,000 liters of human plasma into Albumin, IVIG, and Factor VIII at highly competitive prices.
His leadership blends strategic vision, operational excellence, and an unwavering commitment to ethical, transparent, and accountable organizational culture.
Join us at WHIF25, hosted by Andhra Pradesh MedTech Zone Limited, to hear from leaders like Dr. Ajmani who are driving innovation, ensuring equitable access, and setting new benchmarks in global healthcare.
December 11–13, 2025
Register now.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC